At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
LY2608204 Reference +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Relative Bioavailability of a Proposed Phase 2 LY2608204 Test Formulation Compared With the Current Phase 1 LY2608204 Reference Formulation After Administration of a Single Oral 80-mg Dose in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY2608204 Reference and LY2608204 Test for Healthy Volunteers. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to compare 2 formulations of the study drug (LY2608204) in terms of how much gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionApr 2011
TodayJul 2026
First PostedMar 11, 2011
Enrollment StartMar 1, 2011
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.3 years ago
Interventions
LY2608204 Referencedrug
Administered orally
LY2608204 Testdrug
Administered orally.